skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Pharma R&D Annual Review 2019 Supplement: New Active Substances Launched During 2018

Take the analysis from the Informa Pharma Intelligence R&D Annual Review 2019 further with the Pharma R&D Annual Review 2019 Supplement: New Active Substances Launched During 2018. This essential whitepaper uses critical data from Pharmaprojects to examine the new entities that were successfully launched to market last year.

Using the same extended sports metaphor as the R&D Annual Review 2019, our expert analyst takes you into the world of new chemical or biological entities where the active ingredient had received no prior approval for human use until 2018. Take a look at which new active substance (NAS) drugs, including vaccines with novel antigenic components, crossed the finish line and made it to market last year. Information within this resource includes:

 

  • Critical statistics about 2018’s 68 NAS launches
  • Top companies with NAS launches last year
  • NAS launches by therapeutic group
  • NAS launches by region
  • A year-over-year look at NAS launches with an orphan drug designation
  • Notable firsts among this year’s field of NAS launches
NAS_supplement_whitepaper

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: